<DOC>
	<DOCNO>NCT01369095</DOCNO>
	<brief_summary>The purpose study evaluate efficacy study drug ( BMS-820836 ) compare continued Duloxetine/Escitalopram treatment patient treatment resistant depression ( TRD ) .</brief_summary>
	<brief_title>Efficacy Safety Fixed Doses BMS 820836 Treatment Patients With Treatment Resistant Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men woman age 1865 year ( Argentina minimum age 24 year age ) Patients must able understand nature study , agree comply prescribed dosage regimen , report regularly schedule office visit , communicate study personnel adverse event concomitant medication use . Patients diagnosis Major Depressive Disorder , currently experience Major Depressive Episode , define Diagnostic Statistical Manual Mental Disorders Fourth Edition ( Text Revision ) [ DSM IV TR ] criterion . The current depressive episode must &gt; 8 week duration &lt; 3 year duration . In current Major depressive disorder ( MDD ) episode , patient report history inadequate response 13 adequate trial antidepressant treatment . Patients must 17item Hamilton Depression Rating Scale ( HAMD17 ) total score â‰¥ 18 Screening Baseline . Patients report inadequate response ( le 50 % reduction depressive symptom severity ) three adequate trial antidepressant treatment current depressive episode . Patients fail Duloxetine Escitalopram adequate dose adequate duration current episode .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>